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Thermal degradation of insulin complicates its delivery and
use. Previous efforts to engineer ultra-stable analogs were con-
foundedby prolonged cellular signaling in vivo, of unclear safety
and complicating mealtime therapy. We therefore sought an
ultra-stable analog whose potency and duration of action on
intravenous bolus injection in diabetic rats are indistinguish-
able from wild-type (WT) insulin. Here, we describe the struc-
ture, function, and stability of such an analog, a 57-residue
single-chain insulin (SCI) with multiple acidic substitutions.
Cell-based studies revealed native-like signaling propertieswith
negligiblemitogenic activity. Its crystal structure, determinedas
a novel zinc-free hexamer at 2.8 A˚, revealed a native insulin fold
with incomplete or absent electron density in the C domain;
complementary NMR studies are described in the accompany-
ing article. The stability of the analog (GU 5.0(0.1) kcal/mol
at 25 °C) was greater than that of WT insulin (3.3(0.1) kcal/
mol). On gentle agitation, the SCI retained full activity for>140
days at 45 °C and >48 h at 75 °C. These findings indicate that
marked resistance to thermal inactivation in vitro is compatible
with native duration of activity in vivo. Further, whereas WT
insulin forms large and heterogeneous aggregates above the
standard 0.6 mM pharmaceutical strength, perturbing the
pharmacokinetic properties of concentrated formulations,
dynamic light scattering, and size-exclusion chromatography
revealed only limited SCI self-assembly and aggregation in the
concentration range 1–7 mM. Such a combination of favorable
biophysical and biological properties suggests that SCIs could
provide a global therapeutic platform without a cold chain.
Insulin has long provided a model for biochemical and bio-
physical studies of globular proteins with application to human
health (1). The first protein to be sequenced and the first
recombinant therapeutic protein, insulin is central to the hor-
monal control of vertebrate metabolism. Since its discovery in
1921, the hormone has provided a mainstay of treatment for
diabetes mellitus (2). Whereas insulin itself contains two poly-
peptide chains (A and B) as the proteolytic product of a single-
chain precursor (proinsulin (3)), the hormone belongs to an
ancestral metazoan superfamily of single-chain homologs (4),
including vertebrate insulin-like growth factors (IGFs (5, 6))
and invertebrate neuroendocrine factors (7). This study and
accompanying article (8) drew inspiration from these evolu-
tionary relationships to investigate the structure, stability, and
function of a single-chain insulin analog (SCI)6 with high bio-
logical activity and enhanced thermodynamic stability.
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The structure of insulin (Fig. 1, A–C) has been extensively
investigated by X-ray crystallography (1, 9) and NMR spectros-
copy (10–13). Although stored within pancreatic -cells as
zinc-stabilized hexamers (14), the hormone functions in the
bloodstream as a zinc-freemonomer (6). The native conforma-
tion contains three -helices, two in the A chain (21 residues;
green in Fig. 1C) and one in the B chain (30 residues; blue).
Globular folding is stabilized by two inter-chain disulfide
bridges (cystines A7–B7 and A20–B19) and one intra-chain
bridge (cystine A6–A11). The core is sealed at one face by the B
chain’s C-terminal-strand (residues B24–B28). This-strand
forms an antiparallel -sheet at the classical dimer interface
(Fig. 1B), a building block of zinc insulin hexamers (Fig. 1A) (1).
Substitutions at positions B28 and B29 have enabled design of
rapid-acting insulin analogs for mealtime injection or use in
pumps (15).Whereas clinical use of animal insulins gave way in
the 1980s to recombinant human insulin (16), current thera-
peutic regimens often employ analogs with enhanced pharma-
cokinetic (PK) properties. Their development represented an
early triumph of structure-based protein design in pharmacol-
ogy (2).
Crystallographic studies of an insulin monomer bound to
domain-minimized models of the insulin receptor (IR) (17, 18)
demonstrated that the B chain -strand pivots from the -hel-
ical core to insert in trans between IR -subunit domains (the
N-terminal Leu-rich domain (L1) from one protomer and the
C-terminal element (CT) of the other; for review of IR
domains, see Ref. 6). Such pivoting unmasks an otherwise hid-
den non-polar surface of the A chain (including IleA2 and
ValA3), thereby extending the hormone’s primary receptor-
Figure1.Structuraloverviewand insulinanalogsequences.A, crystal structuresof T6 (porcine insulin; PDBcode4INS (1)), T3R
f
3 (B29–A1 single chain insulin;
PDB code 6INS (19)), and R6 (human insulin; PDB code 1ZNJ) hexamers, as labeled. In each structure, the T state protomers are gray and R state protomers are
green. HisB10 side chains are displayed as stickswith coordinated Zn2 ions as red spheres. The second axial Zn2 ion lies directly behind the first. B, anti-parallel
-sheet dimer interfaceof porcine insulin (PDB code4INS).C,overlay of a T stateprotomerof B29–A1 single-chain insulin (transparent gray; PDB code6INS) and
porcine insulin (PDB code 4INS). The latter displays the A (green) and B (blue) chains and three native disulfide bridges (yellow sticks): A20–B19, A7–B7, and
A6–A11 (black boxed labels). Side chains of WT residues ThrA8 and TyrA14 are highlighted as red sticks. The C-terminal B chain segment (important in both
dimerization and IR binding) is labeled. Red dashed line and asterisk represent C domains of proinsulin and SCIs.D, protein sequences of SCI-a and SCI-b aswell
as progenitor SCI-c (29). Peptide bonds connecting the A and B domains to the C domain are illustrated with red lines. Substitutions relative to WT insulin are
identified by red letters. Gold lines identify the three native disulfide bonds. Black arrows at bottom of D highlight residues B10, B28, B29, and A14, key sites of
substitution.
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binding surface (17, 18). This conformational transition ratio-
nalizes a wealth of prior biochemical data (10, 19–22), includ-
ing early studies of insulin analogs modified by bifunctional
reagents to cross-link the C-terminal segment of the B chain
and the N terminus of the A chain (23, 24). These studies
demonstrated that short cross-links markedly impair IR
binding, whereas longer cross-links could, at least in part,
restore activity.
Studies of SCIs began in the 1980s with the advent of micro-
bial manufacture of insulin (16). Providing trypsin-cleavable
manufacturing intermediates (mini-proinsulins), these recom-
binant proteins contain a peptide bond to theN terminus of the
A chain (GlyA1) from a residue at or near the C terminus of the
B chain (ThrB30) (25, 26). Constrained within a closed confor-
mation, such SCIs (50–53 residues) exhibited favorable folding
properties and hence high manufacturing yield (25, 27), but
theywere essentially devoid of biological activity despite native-
like structures (19, 26) The T3Rf3 crystal structure of B29-A1
mini-proinsulin, like the “dog that did not bark in the night-
time,”7 was remarkable for the absence of perturbations (central
panel in Fig. 1A) (19).
Subsequent studies of single-chain chimeric insulin-IGF
proteins suggested that insertion of the 12-residue IGF-I con-
necting (C) domain between insulin’s ThrB30 and GlyA1 could
restore, at least in part, IR affinity (28). Interest in active SCIs
was first stimulated by potential applications in viral gene ther-
apy.8 Their biophysical properties have been investigated in
relation to insulin fibrillation (29, 30), a form of physical degra-
dation (31) that makes necessary a pharmaceutical “cold chain”
of storage and distribution (32). Circumventing this complex
and costly process defines a current translational goal of insulin
analog design (32, 33).
Here, we describe the structure and function of an active SCI
with sequence features designed to co-optimize its biophysical,
biochemical, and biological properties (SCI-a in Fig. 1D and
Table 1). The C domain contains 6 residues, resulting in a
57-residue protein. To enhance solubility, the protein contains
acidic substitutions predicted to reduce its isoelectric point
from 5.4 (wild-type (WT) insulin)9 to 4.9. Sites of substitution
were chosen to impair binding to the mitogenic type 1 IGF
receptor (IGF-1R) (34, 35) and enhance stability (29, 36). The
crystal structure of SCI-a, obtained herein at 2.8 Å resolution,
depicts a novel zinc-free hexamer containing native-like insulin
folds with apparent disorder in the C domains. Whereas SCI-a
forms classical dimers (Fig. 1B), their hexameric assembly dif-
fers from that of zinc-coordinated two-chain insulin hexamers
(Fig. 1A) (1, 37). In the accompanying article (8) we employed
heteronuclear NMRmethods to investigate the solution struc-
ture and dynamics of a monomeric SCI variant (SCI-b in Fig.
1D). The two SCIs differ at positions B28 andB29 in accordance
with well-established structure–activity relationships underly-
ing past design of rapid-acting clinical analogs (38–40).
This study paid particular attention to the duration of bio-
logical action as defined by the pharmacodynamic (PD) prop-
erties of the insulin analog on intravenous (i.v.) bolus injection.
Because insulin clearance from the bloodstream is 20-fold
more rapid than physiological attenuation of insulin signaling
(41), such studies probe the duration of insulin signaling at
target tissues once the IR is engaged. Previous efforts to obtain
ultra-stable analogs, either by introduction of an additional
disulfide bridge (33) or by design of an active SCI (29), encoun-
tered aberrant prolongation of in vivo glucose-lowering activity
(Fig. S1). Such prolonged signaling would be unfavorable for
prandial or pump-based therapy (15) and could be associated
with adverse biological effects (42).
To our knowledge, SCI-a provides the first example of an
ultra-stable insulin analog whose in vivo duration of action is
similar to that ofWT insulin. The analog exhibits striking resis-
tance to thermal degradation with prolonged retention of bio-
logical activity. Moreover, its cell cycle–related transcriptional
signaling resembles WT insulin and not single-chain homolog
IGF-I ormitogenic insulin analogs (34). Together, these studies
highlight the translational promise of ultra-stable SCIs as a plat-
form for global distribution without the cost and complexity of
a therapeutic cold chain. Such molecular technologies, moti-
vated by the current diabetes pandemic, may be especially
important in the developing world (32, 43).
Results
SCI-a and monomeric analog SCI-b incorporated multiple
design elements for simultaneous optimization of biophysical
and therapeutic properties. These elements were introduced
based on prior studies of two-chain insulin analogs (38, 39) and
a single-chain prototype (SCI-c (29)). Key sequence features
and their rationale are summarized in Table 1. Whereas the C
domain (EEGPRR) contains offsetting negative and positive
charges, the set of substitutions in the A and B domains was
expected to accentuate the proteins’ net negative charge at neu-
tral pH and thereby mitigate both native and non-native aggre-
gation (44).
The SCIs contain exclusively WT residues at the hormone’s
classical (site 1) and accessory (site 2) receptor-binding surfaces
(6, 18). Stabilizing acidic substitutions at residue B10 (Asp or
Glu) was avoided due to their association with enhanced mito-
genicity and carcinogenesis (34). Retention of HisB10 was also
intended to enable zinc-mediated hexamer assembly (1), tradi-
tionally employed to stabilize pharmaceutical formulations
(45). Near the site 1 interface, HisA8 (a feature of avian insulins
(36)) has previously been shown to enhance both stability and
receptor binding, presumably as a more favorable -helical
C-cap residue than ThrA8 (30, 36).
An overarching objective was avoidance of anomalously
prolonged activity on i.v. bolus injection as observed in prior
ultra-stable insulin analogs (Fig. S1). Such prolongation, first
7 From “The Adventure of Silver Blaze,” a Sherlock Holmes short story from
TheMemoirs of Sherlock Holmes by Sir Arthur ConanDoyle first published
in 1892.
8 Clinical use of SCIs was first motivated by viral gene therapy in a study since
retracted by its authors (101).
9 Wild-type insulin pertains to the human sequence unless otherwise stated.
Insulin residues aredenotedby residue type (in standard three-letter code)
followed by chain and position as a superscript (e.g. TyrB16 designates a
tyrosine at the 16thposition of the B chain). Insulin lispro is a clinical analog
that exhibits rapid action due to interchange of residues B28 and B29.
Activity of insulin formulations is standardized in International Units (IU);
standard U-100 formulations contain 100 IUs per ml and correspond to a
WTprotein concentration of 0.6mM. AU-1167 strength formulationwould
thus correspond to7 mM WT insulin.
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reported by Vinther et al. (33) in studies of an insulin analog
stabilized by a fourth disulfide bridge (Fig. S1, A and C), was
reproducible in our hands (black triangles in Fig. S1D) and also
seen in studies of a prior SCI prototype (SCI-c; blue crosses in
Fig. S1D and structure in Fig. S1B). These studies employed
male Lewis rats rendered diabetic by streptozotocin (30). Use of
i.v. bolus injection circumvented PK issues related to the sub-
cutaneous depot (41).
SCI-a and SCI-b each exhibited substantial activity in the i.v.
rat assay (Fig. 2). Results are shown in relation to the absolute
blood-glucose concentration (Fig. 2A) and relative to the start-
ing blood-glucose level (Fig. 2B). The PD profile of SCI-a
(orange circles in Fig. 2) was similar to that of insulin lispro (red
squares), whereas SCI-b exhibited a late tail of insulin action
(green triangles) similar to that of SCI-c (Fig. S1D). The native-
like PD profile of SCI-a implies that its clearance and duration of
cellular signaling are similar to WT insulin. Despite its native
potency in vivo, receptor-binding studies of SCI-a in vitro revealed
decreased affinity for theA (by 5-fold) and B (by 15-fold) isoforms
of the IRwithat least10-fold reduction inaffinity for the type1 IGF
receptor (IGF-1R). The respective receptor-binding affinities of
SCI-b were similarly reduced (Table S2).
SCI-a retains canonical structure as a zinc-free hexamer
The crystal structure of SCI-a was determined as a zinc-free
hexamer to a resolution of 2.8 Å (Fig. 3A). Diffraction statistics
are given in Table 2. The asymmetric unit contained the entire
hexamer, and so the structure provided six independent
protomers (labeled A–F) forming three independent dimers
(AB, CD, and EF). Electron density corresponding to the C
domains was absent as was (to a varying extent among protom-
ers) density corresponding to adjoining residues in the A and B
domains (gray dashed lines in Fig. 3A). Themost completemap
pertained to protomer D (gold in Fig. 3A): weak density was
observed at ProB28 and GlyA1, whereas intervening residues
(sequence ETEEGPRR) were not visualized. The average pair-
wise root-mean-square deviations (r.m.s.d.) amongmain-chain
atoms well-defined in each protomer was 0.75(0.09) Å. Fol-
lowing analogous pairwise alignment and comparison of the
three dimers, mean r.m.s.d. among main-chain atoms was
1.0(0.2) Å.
Each protomer exhibited a canonical T state conformation
(Fig. 3C; porcine insulin monomer 1 as reference structure).
Relative to six reference T state protomers in prior crystal
structures of insulin, themeanpairwisemain-chain r.m.s.d. was
0.71 Å (Table S1A) with a range of 0.60–0.95 Å. Each dimer
likewise conformed to a classical T2 dimer (Fig. 3B). Relative to
reference dimers in two prior crystal structures, the mean
main-chain r.m.s.d. was 1.10 Å with range 0.96–1.33 Å (Table
S1B, left). Higher r.m.s.d. were obtained on comparison of the
SCI-a hexamer with classical insulin hexamers (Table S1B,
right), reflecting a novel change in dimer–dimer orientation
relative to zinc insulin hexamers (1). This observation, aswell as
the potential presence ofmagnesium ion coordination (Fig. 3,D
and E), is further evaluated under “Discussion” (below).
TheabsenceofCdomainelectrondensity suggests its flexibility.
To probe such apparent disorder, SCI-b was prepared as amono-
meric model. Whereas 1H NMR spectra of SCI-a exhibited con-
centration-dependent resonance broadening (Fig. S2, A–D), the
spectrum of SCI-b exhibits narrow resonances even at a concen-
tration of 1mM (Fig. S2E). The solution structure and dynamics of
SCI-b are described in our accompanying article (8).
Table 1
SCI sequence design features and their associated rationale
Design element Rationale
GluC1–GluC2 Isoelectric shift (for enhanced solubility) and hypothesized reduction in IGF-1R cross-binding
GlyC3–ProC4 Facilitates flexible chain reversal in direction of A1–A8 helixa
ArgC5–ArgC6 Mimics the charge pattern of the dibasic cleavage site at the C to A domain junction in proinsulina
HisA8 Stability enhancement through optimization of A1–A8 helical C-capa
GluA14 Protein stabilization through reduction in entropic penalty likely incurred by solvent exposed TyrA14 in the WTb
GluB29 (SCI-a) Formation of stable dimersc
AspB28–ProB29 (SCI-b) Accelerated hexamer/dimer disassemblyd
a Data are as in the SCI-c prototype (29).
b A14 was hypothesized to exhibit the “reverse hydrophobic effect” (103) wherein the WT solvent-exposed and hydrophobic tyrosine side chain would destabilize the folded
state. Replacement with charged (hydrophilic) and solvated GluA14 would ameliorate this effect. Although a GluA14-insulin analog has been previously synthesized (59)
with no significant change in hormone activity, to our knowledge, the isolated contribution of TyrA143 Glu to thermodynamic stability has not yet been determined.
c Data are as in insulin glulisine, a fast-acting clinical analog (40).
d Combination of the designs of fast-acting analogs insulin aspart (39) and insulin lispro (38) is shown.
Figure 2. Rat studies of fresh insulin analog solutions. Shown are rat stud-
ies of insulin action following i.v. injection of 1.7 nmol/300-g rat of the speci-
fied SCI or control.A,blood-glucose concentration;B,percent change relative
to initial blood-glucose concentration. Symbols are defined as inset inA. Sam-
ples sizes: (diluent control) n 12; (insulin lispro) n 13; (SCI-a) n 13; and
(SCI-b) n 10.
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SCIs exhibited enhanced stability and resistance to physical
degradation
Stability was assessed by CD-monitored guanidine denatur-
ation. Free energies of unfolding (GU) were calculated based
on two-state modeling (Table 3). SCI-a (GU 5.0(0.1) kcal/
mol) is 2 kcal/mol more stable than insulin lispro (3.0(0.1)
kcal/mol); under these conditions the stability of WT insulin
was reported to be 3.3(0.1) kcal/mol, in accordance with
prior studies (46). SCI-b was somewhat less stable than SCI-a
(GU 0.3(0.2) kcal/mol) as expected based on its B28–
B29 element (47). These assays predict that formulations of
SCI-a and SCI-b would exhibit slower rates of chemical deg-
radation (45).
Susceptibility to physical degradation, defined as aggrega-
tion-coupled misfolding without breakage of chemical bonds,
was assessed through measurement of lag times in fibrillation
assays (30, 45). The studies were performed in glass vials at a
protein concentration of 0.6 mM (corresponding to WT U-100
formulations) at 45 °C with gentle agitation in the presence of
an air–liquid interface. Such conditionsmimicked insulin solu-
Figure3. SCI-a crystal structure andelectrondensitymap.A, ribbonmodel of novel zinc-free hexamer. Electrondensities of the B1–B4, B27–B30, andC1–C6
segments were poor in all SCI-a monomers; gray dashed lines (connecting -carbons) in each monomer denote missing C domains in the hexamer. B and C,
backbone superpositionof all SCI-a dimers (color schemeas inA) alignedaccording to themain-chain atomsof residuesA1–A8, A13–A19, andB9–B19 (helices)
of the 4INS dimer (gray) (B) and all SCI-a monomers aligned according to the above main-chain atoms in 4INS monomer 1 (gray) (C). NA, CA, NB, and CB labels
respective chain termini of theAandB chains of 4INS; the termini of oneSCI-amonomer (brown) are likewise labeledbyN andC. Disulfidebonds arenot shown.
D, SCI-a hexamer with residues B9, B10, and B13within hexamer core displayed as sticks. The gray boxed region is expanded in the stereo view of the core in E.
E, stick representations of residues B9–B13 and underlying electron density (2mFo DFc; graywire frame). Side-chain labels are provided aswhite textwith
black outlines. Atom colors: pink/red, oxygen, and blue, nitrogen; carbons are colored as in respective monomers in D.
Table 2
Crystallographic data collection and refinement statistics for SCI-a
Data collection
Source SSRL BL7-1
Wavelength (Å) 1.12709
Space group P21
Unit cell dimensions a 43.382, b 85.771, c 45.696 Å
 110.89°
Resolution (Å) 38.22–2.80 (2.95–2.80)a
Rmerge (%) 5.6 (30.9)
I/I 15.2 (3.6)
Completeness (%) 99.3 (96.0)
Redundancy 3.7 (3.5)
No. of reflections 7718
Refinement
Resolution (Å) 38.22–2.80
R-factor/RFree (%) 25.10/31.42
No. of protein atoms 2155
r.m.s.d. bond length (Å) 0.007
r.m.s.d. bond angle (°) 1.098
Average B-factors (Å2)
Chain A 78.5
Chain B 79.5
Chain C 59.8
Chain D 69.1
Chain E 84.1
Chain F 54.4
Ramachandran plot (%)
Most favored region 94.8
Additionally allowed regions 4.8
Generously allowed regions 0.4
Disallowed regions 0.0
a Values in parentheses are for the highest resolution shell.
Table 3
CD denaturation and fibrillation studies
Analog GUa m-valueb Cmidc
Fibrillation lag
time (days)d
kcal/mol kcal/(molM) M
WT insulin 3.3 0.1 0.69 0.01 4.8 0.1 5.3 0.5
lispro 3.0 0.1 0.63 0.01 4.7 0.1 4.3 0.2
SCI-a 5.0 0.1 0.86 0.01 5.8 0.1 140
SCI-b 4.7 0.1 0.82 0.01 5.7 0.1 110
a Data are from two-state modeling of CD-guanidine titrations performed at 25 °C
and pH 7.4.
b Them-value (units of kcal/(molM)) is the slope of unfolding free energy GU
versusmolar concentration of denaturant.
c Cmid is the guanidine denaturant concentration at which 50% of the protein is in
the unfolded state.
d SCI analogs at U-100 concentration were gently rocked in triplicate at 45 °C in
modified Lilly diluent containing Zn2 ions, wherein Tris-HCl was substituted
for sodium phosphate buffer. WT insulin and lispro fibrillation studies utilized
gentle rocking at 45 °C of the pharmaceutical formulations Humulin and
Humalog, respectively; both are U-100 strength in Lilly diluent. Error in asso-
ciated lag times is the standard deviation of triplicate samples.
Heat-stable insulin engineering
J. Biol. Chem. (2018) 293(1) 47–68 51
tions transported in the developing world without benefit of a
cold chain (32). Whereas WT insulin (Humulin) and lispro
(Humalog) were observed to begin fibrillation within a few
days, fibrillation of SCIs was not observed despite prolonged
thermal stress (Table 3).
SCIs exhibited enhanced solubility with decreased
aggregation
To assess solubility and aggregation, SCIs in Zn2-contain-
ing solutions compatible with pharmaceutical formulation
were studied by turbidimetry (Fig. 4A) and rp-HPLC (Fig. 4B).
WT insulin at pH 7.4 began to precipitate between 5 and 7mM.
Whereas at 7 mM 	60% of WT insulin was HPLC-detectable
after centrifugation (Fig. 4B), the SCIs at 7 mM were fully
recoverable.
Protein aggregation was probed by size-exclusion chroma-
tography (SEC; Fig. 4C). Samples were made 1–7 mM and
diluted on entrance to the Zn2-free mobile phase and SEC
matrix. As this simulates dilution and clearance of formulation
buffer upon subcutaneous injection, zinc-coordinated species
Figure 4. Studies of protein self-assembly and aggregation. A, concentration dependence of optical absorbance at 500 nm (turbidimetry (78)); insulin
analogs were dissolved in Tris-HCl buffer (pH 7.4) containing zinc, phenol, andmeta-cresol. Error bars represent the standard deviation of fourmeasurements.
B, studies of protein solubility; rp-HPLC-based estimates are presented as fraction of protein recovered after centrifugation. Error permeasurement in B is fixed
at 10% to reflect deviations between multiple injections of 10-g Humalog standard (see “Experimental procedures”). C, SEC of insulin analogs at stated
concentrations (7, 5, and 1 mM). Elution peaks are labeled with calculated masses (in kDa) as interpolated from a set of molecular mass standards (see under
“Experimental procedures” and Fig. S5). D and E, dynamic light scattering. Field autocorrelation functions (D, solid lines are fits) and inferred size distributions
(E) by the regularizationmethod (91) for insulin analogs at stated concentrations. Blue arrow in E highlights presence of large aggregates ofWT insulin at 5mM.
Color code: WT insulin, blue; SCI-a, green; and SCI-b, red.
Heat-stable insulin engineering
52 J. Biol. Chem. (2018) 293(1) 47–68
such as hexamers are not observed (46). At 5–7mMWT insulin
eluted as a heterogeneous mixture of oligomers with masses
between those of the dimer (12 kDa) and hexamer (35 kDa);
peaks were observed at 23.2 and 17.6 kDa. At 1 mM, the elution
time corresponded to amass of 8.3 kDa, providing evidence of a
monomer–dimer equilibrium. Although also heterogeneous,
SCI-a at 5–7 mM was less polydisperse than WT insulin; its
elution time corresponding to a mass of 12.2 kDa, close to that
predicted of an SCI dimer. At 1 mM, SCI-a yielded an elution
profile similar to that ofWT insulin. SCI-b eluted as amonomer
(6.2–7.2 kDa) at all concentrations tested. For all samples, noV0
peak corresponding to elution of aggregates larger than the col-
umn molecular weight range were observed.
We further evaluated the distribution of protein aggregates
in the presence of zinc-containing formulation buffer by
dynamic light scattering (DLS; Fig. 4, D and E), which is more
sensitive to large aggregate formation than SEC. All analogs
form hexamers in the above concentration range, as indicated
by the presence of hydrodynamic radii (Rh) between 2 and 3nm.
Although it was difficult to distinguish the DLS signatures of
insulin monomers and dimers (Rh1–2 nm) from that of hex-
amers (Rh 2.8 nm) due to similar translational diffusion rates
(48), at 7 mM bothWT insulin and SCI-a exhibited a combined
monomer–dimer–hexamer signal.
WT insulin also formed large aggregates with radii 1000
and 10,000 nm, the signal from such higher-order aggregates
was attenuated in the SCI solutions as indicated by (i) rarer
bursts in count rate associated with large aggregates at each
protein concentration, and (ii) comparative studies at 5 mM
at which only WT insulin forms micron-sized species.
Smaller aggregates (Rh 100–150 nm) were weakly detect-
able in all 1 mM solutions, in part due to the disproportionate
sensitivity of DLS to larger aggregates relative to smaller
assemblies (48).
SCIs were refractory to thermal inactivation
To assess thermal inactivation, an SQ rat assaywas employed
to test activities of protein solutions following gentle agitation
at 45 or 75 °C (upper panel in Fig. 5A); conditions were as
described for the fibrillation lag-time assay (above). Fractional
areas under the curve (AUC; lower panel at center in Fig. 5A)
were extracted to estimate fractional changes (upper right-
hand panel) and percent maintenance of activity (lower right-
hand panel). Results demonstrated that the SCIs exhibited pro-
longed retention of activity under conditions wherein current
clinical analogs degraded (Fig. 5, B–E). Thus, SCI-a and SCI-b
both remain fully active when incubated at 45 °C with gentle
agitation for 140 days (SCI-a) and 111 days (SCI-b), whereas
essentially complete inactivation of standard analogs insulin
lispro (after 5 days) and insulin glargine (after 11 days) was
observed (Fig. 5,B andD). Similar trendswere obtained at 75 °C
(Fig. 5, C and E).
SCIs exhibited no increase inmitogenic signaling relative to
WT insulin
Cellular signaling was assessed in two cell lines: rat L6 myo-
blasts overexpressing insulin receptor isoform A (L6-IRA (49))
and humanMCF-7 breast cancer cells (50); the latter expresses
human IGF-1R and to a lesser extent IR isoforms A (IR-A) and
B (IR-B) (50). Following exposure to 100 nM hormone (WT
insulin, SCI, or control analogs; top left in Fig. 6A), transcrip-
tional activation of mitogenic/proliferative pathways was
assessed by real-time quantitative PCR (rt-qPCR; schematic at
bottom right in Fig. 6A). In addition, ligand-dependent IR tyro-
sine phosphorylation and Akt serine phosphorylation were
probed by Western blotting as respective probes of receptor
activation and post-receptor signaling (top right in Fig. 6A; Ref.
51). A flowchart describing these assays and their rationale is
provided in Fig. S3. These blots were performed to verify that
analogs inducing reduced mitogenic transcriptional activation
still execute a significant insulin-stimulated response from the
L6-IRA and MCF-7 cells.
In the rt-qPCR assay mitogenic analogs AspB10-insulin
(labeled “X10”) and IGF-I (34) effected a reduction in cyclin G2
transcription with an increase in cyclin D1 mRNA accumula-
tion (Fig. 6, B andD). By contrast, WT insulin and lispro exhib-
ited decreased cyclin D1 activation and cyclin G2 repression.
The rt-qPCR signatures of SCI-a and SCI-b resembled WT
insulin and lispro and were distinct from the rt-qPCR signa-
tures of AspB10-insulin or IGF-I (Fig. 6, B andD).Western blot-
ting revealed that the SCIs nonetheless stimulated IR and Akt
phosphorylation to an extent similar to or greater than WT
insulin or lispro (Fig. 6, C and E; see also Fig. S4).
Discussion
Proinsulin, the biosynthetic precursor of insulin, is a single
chain with domain organization B–C–A (3). Flanked by dibasic
sites, the 35-residue C domain is excised by prohormone con-
vertases in pancreatic -cells, yielding the mature two-chain
hormone (52). Vertebrate C domains vary in length (30–35
residues) and are less well conserved than are the A and B
domains (Table S3) (53). Although proinsulin binds to IR iso-
forms more weakly than does WT insulin (relative affinity 5%)
(54), the precursor retains substantial biological activity in vivo
(55). Its therapeutic efficacy was evaluated in the 1980s as a
partial hepatoselective agonist (55). Although clinical trials
were terminated due to excess cardiovascular deaths (55), these
data provided proof of principle for an SCI-based regimen.
Our interests have focused on insulin analogs that are less
susceptible to physical and chemical degradation than WT
insulin or current clinical analogs (32). Such degradation is
exacerbated above room temperature (31, 45), leading to guide-
lines from the United States Food and Drug Administration
regarding the distribution, storage, shelf life, and disposal of
pharmaceutical formulations (56). A particular problem is
posed by the susceptibility of two-chain analogs (i.e. all current
insulin products) to fibrillation (31). Because creation of an
amyloidogenic nucleus (“seeds”) can occur on their transient
exposure to moderately high temperatures (31) and because
such seeding can accelerate fibrillation even in refrigerated
solutions (57), distribution of insulin formulations presently
requires a complex and costly cold chain (32, 43). Implications
for global health have been deepened by an emerging pandemic
of type 2 diabetes mellitus (32, 43).
In this and our accompanying article (8), we have investigated
the structure and function of an ultra-stable SCIwith a six-residue
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Cdomain. The connecting domain sequence (EEGPRR) contains
offsetting negative (bold) and positive (italics) charges. The
former elementwas introduced to disfavor binding to IGF-1R, a
receptor associated with mitogenic signaling (58), whereas the
latter (mimicking the natural dibasic site) was intended to
interact with GluA4 (29) to stabilize the adjoining A domain
Figure 5. Rat studies of heat-stressed insulin analogs. A, schematic diagram of the thermal inactivation assay wherein formulations of insulin at U-100 (0.6
mM) in septum-sealed glass vials are gently rocked in an oven set to either 45 or 75 °C. At the indicated times, the vials were removed followed by dilution and
SQ injection intodiabetic rats to assess residual potency.Bottompanel ofA shows the resultingglucose-response curves for a fully active (black) andcompletely
dead analog (red), the latter of which would give an identical curve to a diluent-only control. These curves are integrated and processed to provide AUC and
AOC. These metrics provide fractional AUC, a reporter of significant differences between the fresh and heated analog data, and percent activity, which
illustrates degree of inactivation following heating. Fractional AUC for the stated fresh (white) or heated (gray) analogs are given for 45 °C (B) and 75 °C (C)
experiments. Heated incubation times are given below the appropriate analog name. Percent (%) activities for the experiments in B and C are given in D and
E. *,p	0.1; **,p	0.05,ns,not significant (p0.1). Sample sizes for eachSQexperimentweren4–5 rats andanalogdoses ranged from3.0 to6.0nmol/300-g
rat.Doses in this rangedonotproduce significantlydifferentglucose-responseprofiles. Thedoseand sample sizeof anygivenanalog setwas the same for fresh
and heated injections.
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-helix (residues A1–A8), an unstable “Achilles’ heel” in the
mechanism of insulin fibrillation (30). The central GlyC3–
ProC4 element (underlined above) was intended to promote
flexible chain reversal. SCI-a also contained substitutions in the
A and B domains intended to augment stability, solubility, and
receptor binding in accordance with previous studies of two-
chain analogs (Table 1) (36, 59). Substitution of HisB10 by Asp,
incorporated in a previous SCI design (29) to augment sta-
bility and activity (SCI-c in Fig. 1D), was excluded due to its
association with elevated mitogenicity and carcinogenesis in
rats (34, 60). Because these adverse effects may, at least in part,
reflect the enhanced affinity of AspB10-insulin for the IR iso-
Figure 6. Cell biological assessment of insulin signaling. A, schematic outline of cell-based assays for the assessment of hormone-induced IR-A signaling
and activation of mitogenic pathways. L6 rat myoblasts stably expressing human IR isoform A (IR-A) (developed by De Meyts and co-workers (49)) or MCF-7
humanbreast cancer cells expressingboth IR isoforms (IR-A and IR-B) andhigh levels of IGF-1R (50)were treatedwith SCI analogs or control two-chain analogs.
After 15min of treatment, Tyr-phosphorylation of IR and Akt was assessed byWestern blotting (51) (upper flowchart). To analyze relativemitogenic potencies,
L6-IRA or MCF-7 cells treated for 8 h were collected, and the transcriptional response of cell proliferationmarkers cyclin D1 and cyclin G2 (cell cycle schematic
adapted from Ref. 102) was assessed by rt-qPCR (schematic adapted from Bio-Rad). The increased accumulation of cyclin D1 and decreased cyclin G2 mRNA
served as readouts for insulin-induced activation of cellular proliferation pathways (bottom flowchart). B, assessment of insulin-driven cyclin D1 and G2
transcription in L6-IRA cells; known mitogenic analogs (dashed box) yield increased accumulation of cyclin D1 mRNA and repression of cyclin G2. Brackets
designate p values: *, 	0.05, or **, 	0.01; ns indicates p values 0.05. C, histogram representation of the average fold increase over diluent and dot-plot
representation of the actual fold increase over diluent for each data point collected from L6-IRAWestern blottings of p-IR/IR (left) and histogram average and
actual dot-plot representations of the ratio of p-Akt to total cell Akt obtained from L6-IRA blots of p-Akt/Akt (right). D and E, studies in a human breast cancer
cell line. MCF-7 cell-derived rt-qPCR (D) and phosphorylation Western blot data (E) are presented as in B and C. Histograms: n 3; standard error. ** or *
indicates p value	 0.01 or	0.05.Whiskers for the dot-plot follow Tukey’s box plotmethod: lowest data point within 1.5 Interquartile Range (IQR) of the lower
quartile, and the highest data point within 1.5 IQR of the upper quartile. Abbreviations: Con, diluent control; X10, AspB10-insulin; WT insulin; KP, insulin lispro.
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forms and IGF-1R (relative affinities 200%) with increased
residence times (34), our design criteria tolerated relative affin-
ities 	100% in cell-free assays provided native potency was
maintained in vivo.
Previous efforts to engineer ultra-stable insulin analogs
encountered a puzzling prolongation of signaling on i.v. bolus
injection (Fig. S1) (33). Such extended duration of activity was
observed, for example, in otherwise elegant studies of two-
chain analogs stabilized by a fourth non-canonical disulfide
bridge (33). This PD perturbation presumably reflected an
alteration in cellular events that mediate termination of insulin
signaling. Analogous perturbations have not been observed in
studies of current long-acting insulin products, whose pro-
tracted action reflects conventional PK properties rather than
delayed signal termination by target cells (61). Irrespective of
molecular mechanism, such prolonged signaling would pre-
clude use in insulin pumps and raise safety concerns on chronic
administration (42).
Unlike the above analog (33) and our prior SCI prototype
(sequence SCI-c at bottom in Fig. 1D (29, 62)), i.v. bolus injec-
tion of SCI-a in streptozotocin-induced diabetic rats was found
to reproduce the PD profile similar to that of insulin lispro (Fig.
2).Modification of the B domain in SCI-b (intended as amono-
meric NMR model; see accompanying article (8)) nonetheless
conferred a delayed “tail” in blood-glucose recovery. This tail
exhibited greater prominence in SCI-c (Fig. S1D). Biochemical
principles relating SCI sequence to duration of action in vivo
are not presently understood. The native-like PD properties of
SCI-a motivated studies of its structure, stability, and possible
mode of receptor binding as discussed in turn.
Crystal structure reveals native-like subunits in novel hexamer
The compatibility of the canonical insulin fold with direct
B-A peptide bonds or with C domains of variable length reflects
the native proximity of the C terminus of the B domain and N
terminus of the A domain (25, 26, 63). Although ThrB30 is dis-
ordered in some crystal structures (37) and exhibits motional
narrowing in solution structures of engineered insulin mono-
mers (12), in a subset of crystallographic protomers a salt bridge
has been observed between theC-terminal B30 carboxylate and
the N-terminal amino group of GlyA1 (1). We thus anticipated
that the crystal structure of SCI-a would depict native insulin
folds with preservation of a canonical dimer interface.
Crystallographic analysis of SCI-a at moderate resolution
(2.8 Å) indeed revealed an ordered and native-like -helical
subdomain (spanning residues B4–B19 andA1–A21); its dimer
interface (including dimer-related antiparallel -sheet; B24–
B28 and B28
–B24
) was similar to that of WT insulin (37).
Unusually, the structure was obtained in the absence of zinc
ions and presence of high concentrations of magnesium ions.
The only existing zinc-free insulin hexamer crystallized de novo
required GluB13 3 Gln substitution to alleviate electrostatic
repulsion within the hexamer (64). Near-complete extraction
of zinc ions from WT T6 hexamers on soaking 2-Zn insulin
crystals with EDTA yielded native-like hexamers (65). Neither
of these prior structures anticipated the shift in dimer–dimer
orientations observed in the present crystal structure.
SCI-a by contrast retains GluB13. Althoughmetal-ion density
in the SCI-a hexamer core (Fig. 3, D and E) was not observed
due to either diffraction resolution limitations or ion static or
dynamic disorder, magnesium coordination or binding is pos-
sible. Packing defects among HisB10 and GluB13 side chains
were observed (top half of Fig. 3E). It is possible that protona-
tion of the B10 imidazole rings may offset the negatively
charges of GluB13; the side chains of SerB9 may also participate
in stabilizing hydrogen bonds (lower half of Fig. 3E). It would be
of future interest to measure the pKa values of HisB10 and
GluB13 in such a metal-ion-free hexamer to allow their proto-
nation states to be inferred. The free space surrounded by these
negatively charged and polar residues could be occupied by an
interacting magnesium cation, magnesium hydrate, or possibly
hydronium molecules.
Evidence for disorder in the crystal state was provided by
qualitative features of the electron-density maps. In this crystal
form the asymmetric unit was the hexamer itself, and so three
independent views of the SCI dimer were obtained, in turn pro-
viding six views of theCdomain. Each dimer exhibited a canon-
ical interface with discontinuous electron density between B27
andA1. Inmostmonomers, density in this regionwas not inter-
pretable. An exception, monomer D included some density for
residues B28–B29 and C6. Although static disorder in the lat-
tice can in principle contribute to such attenuated or discontin-
uous electron density, the consistency of these findings moti-
vated design of SCI-b to enableNMRstudies as described in our
accompanying article (8).
The structure of the SCI-a hexamer exhibits a novel change
in dimer–dimer orientations relative to canonical T6, T3Rf3,
and R6 zinc-insulin hexamers (structures given in Fig. 1A) (9,
19, 37, 64). Specifically, the trimer interface (Fig. 7), which is
composed of the three independent dimers (AB, CD, and EF), is
unprecedented.With alignment of AB dimers (Fig. 8,A–C), the
other two dimers (CD and EF) in SCI-a are rotated about
24–26° (Table 4) relative to their usual orientation in T6
insulin. This large deviation results in high pairwise r.m.s.d.
between SCI-a and classic T6 hexamers (Table S1B, right).
Alignment of EF dimers or CD dimers (Fig. 8, D and E, and
Table 4) produces similar transformations for the remaining
dimers, although the axis of rotation/translation shifts away
from the dimer center of mass. The average rotational devi-
ation of non-aligned dimers (Table 4) is 28(4)°. Whereas
WT T6 hexamers are symmetric, the SCI-a hexamer is asym-
metric as shown by alignment of dimer AB to CD of a repli-
cated structure (Fig. 8F).
It is possible that the zinc-free crystal structure of SCI-a
(schematically represented as ellipsoids in Fig. 9B) is of biolog-
ical relevance. Proinsulin translation and oxidative folding
occurs in the ER of -cells (Fig. 9A, left). After folding and upon
(i) transit through Golgi apparatus and (ii) packaging into
immature secretory granules (66), the C domain is cleaved by
specific prohormone convertases (52) at dibasic sites in the BC
andCA junctions. Themature hormone is stored (Fig. 9A,mid-
dle) as Zn2-stabilized hexamers within specialized secretory
granules (67), which dissociate upon secretion into the portal
circulation (Fig. 9A, right). SCI-a is the first GluB13-containing
insulin to form zinc-free hexamers de novo. Building upon this
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observation, it is possible that proinsulin forms zinc-free hex-
amers in the ER and/orGolgi where zinc content is typically low
([Zn2]ER 0.9 pM and [Zn2]Golgi 0.6 pM inHeLa cells (68))
to enable zinc-dependent self-assembly. The novel dimer ori-
entations (mean28° rotation relative to classic T6 dimers) in
the SCI-a hexamer, which is zinc-free but may contain magne-
sium ions that are either disordered or unseen at 2.8 Å resolu-
tion, may reflect those within the hypothetical zinc-free proin-
sulin hexamers in the ER and/orGolgi (Fig. 9B) that, upon entry
into secretory granules via the ZnT8 transporter (67) and coor-
dination to Zn2, acquire the dimer orientations of classic T6
insulin (Fig. 9C).
Table 4
Orientation of SCI-a dimers relative to T6 hexamers
Aligned dimera Transformed dimerb Rotation Translation
° Å
AB CD 26.00 0.90
AB EF 24.20 1.70
CD AB 24.06 1.63
CD EF 33.58 0.53
EF AB 26.10 0.00
EF CD 33.67 0.37
Mean (S.D.) 27.9 (4.5) 0.9 (0.7)
a “Aligned dimers” in SCI-a were first aligned to the same dimer in T6 human in-
sulin (PDB code 1MSO) by the backbone atoms of helices A1–A8, A13–A19,
and B9–B19.
b Transformations necessary to align the “Transformed Dimer” in SCI-a to its
counterpart in 1MSO were calculated in PyMOL and are presented as degrees
rotation and angstrom translation (along the axis of rotation).
Figure 7. Self-assembly surfaces of insulin and novel SCI-a hexamer. A, color-coded sequence of WT insulin. Residues at dimer interface (blue), trimer
interface (green), or metal ion binding in the hexamer (pink) are highlighted. B, classical 4INS T6 hexamer with trimer interface of monomer B (gray) and
monomer C (green) boxed in red.C, stereo viewof red-boxed region inAwith residues at the trimer interface (B17, B18, A12, A13, andA17) fromboth protomers
shown as sticks.D, stereo view of SCI-a trimer interface with appropriate residues highlighted as sticks. 4INSmonomer C is a gray ghost to highlight its rotation
relative to its counterpart protomer C in SCI-a. For this, dimer AB of 4INS was aligned to dimer AB of SCI-a. Color code: red, oxygen; blue, nitrogen; carbons are
colored as in schematic monomer representations.
Figure 8. Structural relationship between SCI-a hexamer and classical T6 zinc hexamer. Shown are minimized cylindrical representations showing only
the B9–B19 helices of SCI-a (green) and T6 human insulin (PDB code 1MSO (37); blue). A, alignment of dimer AB of SCI-a to dimer AB of 1MSO via the backbone
of all threenativehelices.Redbarsdrawn in3Ddenote theaxis of rotationaboutwhichdimersCDandEFmust independentlybe translatedand rotated toalign
to the classic T6 arrangement of dimers CD and EF in 1MSO. B and C, enlarged views of alignment in Awith independent alignment transformations for dimers
CD and EF, respectively. Alignment viamain-chain atoms of the three-helices and their dimer-relatedmateswithin dimer CD to CD (D) and dimer EF to EF (E);
independent alignment vectors for remaining dimers (red bars) are illustrated in A. F, dimer CD of an SCI-a copywas aligned to dimer AB of the original (green).
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SCImight bind to the receptor via threading ofCT
In accordance with an extensive prior literature (19, 20, 22),
recent crystallographic studies of insulin bound to a domain-
minimized insulinmicro-receptor (IR) demonstrated that the
B24–B27 segment of insulin is displaced from its classical pack-
ing against the A1–A8 and B9–B19 -helices (17, 18). Effected
by changes in Ramachandran dihedral angles flanking PheB24,
this “unhinging” (by60° relative to classical crystal structures
of the free hormone dimer or hexamer (17, 18)) enables con-
served non-polar surface (spanned by the side chains of IleA2,
ValA3, PheB24, and PheB25) to engage the receptor (17, 18). An
extended B24–B27 segment lies in a groove between receptor
elements L1 and CT (17, 18). Residues B28–B30, not well
conserved among vertebrate insulins and dispensable for activ-
ity (1), were presumed to be disordered in the IR complex.
Accordingly, these three residues would amplify the orienta-
tional freedom of the C domain as a flexible tether between
ThrB27 and GlyA1 at the hormone–IR interface.
To enable IR binding, we speculate that the B domain of
SCI-a undergoes a change in conformation similar to that
observed in WT insulin on IR binding (residues B23–B27;
black strand in Fig. 10A). An essential feature of this co-crystal
structure is the reposition of CT (purple ribbon in Fig. 10A)
over the surface of L1 (powder blue) to occupy space ordinarily
taken (in insulin’s free conformation) by the C-terminal seg-
ment of the B chain (green strand). In the WT insulin–IR
complex the B24–B30 segment must pivot both (a) to re-posi-
tion conserved aromatic residues PheB24, PheB25, and TyrB26
and (b) to expose the conserved aliphatic side chains of IleA2
and ValA3 (data not shown). The C domain in the free hormone
(dashed line in Fig. 10A), extended by flexible residues B28–
B30, must therefore reposition to span the gap between ThrB27
and GlyA1 at theIR interface (red arrow in Fig. 10A). Thus, we
envision that in the bound state SCI-a would open a hole
through which CT would “thread.” A similar “threading
model” may pertain to homologous IGF–IGF-1R complexes
(69). To test the plausibility of this model, molecular dynamics
simulations of an SCI bound to the IR complex are described
in our accompanying article (8).
Enhanced stability predicts resistance to chemical and
physical degradation
SCI-a exhibits enhanced thermodynamic stability relative to
WT insulin (GU  1.7 kcal/mol as inferred from chemical-
denaturation studies; Table 3). This estimate was based on two-
state modeling (46), which may introduce baseline fitting arti-
facts in the presence of considerable resistance to denaturation.
Nevertheless, the reliability of thismethodwas corroborated by
our companion NMR studies (8). Previous studies of the sus-
ceptibility of insulin analogs to chemical degradation suggested
that such a change in GU predicts reduced rates of a variety of
processes (breakage or rearrangement of disulfide bridges, scis-
sion of peptide bonds, deamidation of Asn, and formation of
iso-Asp) that can impair activity and confer immunogenicity
(45). Such processes are likely to be faster in the unfolded state
than in the native state.
The SCIs demonstrated remarkable resistance to physical
degradation as probed by fibrillation assays at elevated temper-
atures (Table 3) and associated rat studies of heat-stressed pro-
tein solutions (Fig. 5). Insulin fibrils (transmission electron
micrograph in Fig. 10B), like pathological amyloid deposits in
general (70), are thought to arise fromnucleation by non-native
aggregates (71). Lag times in kinetic studies of protein fibril-
lation reflect rare intermediate conformational fluctuations
among distorted monomers, whose aggregation can provide
amyloidogenic nuclei (Fig. 10C) (30). A variety of evidence
suggests that splaying of the B chainC-terminal strand from the
-helical core promotes insulin fibrillation (29, 31, 71, 72).
Whereas mature fibrils (far right in Fig. 10C) presumably rep-
resent the true thermodynamic ground state of insulin as a het-
eropolymer, the closed conformation of the B chain and its
native self-assembly thus protect the hormone from physical
degradation (far left in Fig. 10C).
We suggest that the foreshortened C domain in SCI-a and
SCI-b provides a topological barrier to amyloid formation (29,
30). By delimiting the extent to which B30 may separate from
A1, an SCI whose C domain is below a critical length imposes a
partial or total block to nucleation (blocked arrows in Fig. 10C).
This model assumes that in an insulin protofilament the A
and B domains undergo a substantial  3  transition in
accordance with fiber diffraction studies (70). Because pro-
insulin is susceptible to fibrillation, its long C domain (35
residues) must confer sufficient conformational flexibility to
enable packing of the distorted A and B domains within the
fibril’s cross- assembly (73). It would be of future interest to
determine a 3D structure of an insulin protofilament in rela-
tion to the free and IR-bound structures of a foreshortened
SCI.
Figure9. Insulin self-assembly in-cell-specific biosynthetic pathway.A,
proinsulin biosynthesis in the -cells begins in the rough endoplasmic retic-
ulum (rER) (left) followed by trafficking through the Golgi apparatus (middle)
and storage into zinc-insulin granules, ultimately leading to glucose-regu-
lated secretionwithdisassembly in thebloodstream (right).B, ellipsoidmodel
of SCI-a zinc-free hexamer. Each ellipsoid represents an insulin dimer; mono-
mers are denoted by blue or yellow. Dashed lines indicate disordered C
domains on hexamer surface. Each ellipsoid is rotated an average of 28° rela-
tive to the bottom ellipsoid (see Table 5). C, correspondingmodel of classical
T6 zinc insulin hexamer with two axial zinc ions (red sphere; the second axial
zinc ion is hidden directly behind sphere). Packaging of WT insulin hexamers
into zinc-containing storagevesicles is enabledbygranule-specific zinc trans-
porter ZnT8 (67).
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SCI-a and IGFs exhibit similar structures but differ inmitogenic
signaling
IGF-I and IGF-II are insulin-like peptides with 40%
sequence identity to insulin and similar 3D structures; their
domain organization is similar to an SCI (74) with the addition
of a C-terminal D region. Analogous to that of SCI-a in this
study, crystal structures of IGF-I and IGF-II typically exhibit
poorly defined density in the C region (69, 74), suggesting con-
formational flexibility or disorder. Furthermore, crystallization
of IGF-I and IGF-II has required a binding partner, such as an
IGF-binding protein, an IGF receptor fragment, anti-IGF anti-
body, or detergent molecule, presumably to prevent non-spe-
cific aggregation and reduce conformational flexibility of the
monomer (74, 75). IGFs do not form ordered hexamers analo-
gous to those of insulin due to GluB10, LysB28, and ProB29 (res-
idue positions 9, 27, and 28 in IGF-I). GluB10 would be expected
to block axial zinc coordination, whereas LysB28 and ProB29
would impair dimerization as in insulin lispro. NMR studies of
IGFs are discussed in our accompanying article (8).
The signaling activities of the SCIs (in comparisonwith those
of WT insulin, AspB10–insulin, and IGF-I) were tested in (i) L6
rat myoblast cells with exogenous overexpression of human
IR-A and (ii) MCF-7 human mammary adenocarcinoma cells
(50) expressing high levels of IGF-1R and, to a lesser extent,
IR-A and IR-B. The proliferative phenotypewas correlatedwith
representative gene-regulatory markers (encoding cyclin D1
and cyclin G2) as evaluated by rt-qPCR. The biological signa-
ture of cell-cycle progression, as probed by transcriptional acti-
vation (cyclinD1) or repression (cyclinG2), has previously been
validated by DeMeyts and co-workers (34) at the protein level;
our assay monitored the analogous process at the level of
mRNA accumulation. Because of its technical simplicity and
reproducibility, we believe that the rt-qPCR approach enhances
the utility of such assays to probe differences in mitogenic sig-
Figure 10. Open state of receptor-bound insulin and its implications for mechanism of fibrillation. A, crystal structure of WT insulin (A chain, yellow; B
chain, black) bound to the IR (17). The B24–B30 segment (black; only observed up to B26) of WT insulin inserts between IR L1 (blue) and CT (pink) domains
(18). The classical (unbound) conformation of the insulin B chain is displayed in green; aromatic side chains B24–B26 in the unboundmonomer are presented
as sticks. Dashed line and asterisk indicate a schematic C domain in unbound SCI-a. The red embossed arrow indicates that the C domain of the bound SCI may
wrap about the CT segment of the IR in an SCI-CT threadingmotif. This panel was adapted from Pandyarajan et al. (90) with permission of the authors. This
researchwas originally published in the Journal of Biological Chemistry. Pandyarajan, V., Phillips, N. B., Rege, N. K., Lawrence,M. C.,Whittaker, J., andWeiss,M. A.
Contribution of TyrB26 to the function and stability of insulin: structure-activity relationships at a conserved hormone-receptor interface. J. Biol. Chem. 2016;
291:12978–12990.© theAmerican Society for Biochemistry andMolecular Biology.B, transmission electronmicroscopy imageofmature insulin fibrils induced
by heat (reproduced with permission from Ref. 72). This research was originally published in Journal of Biological Chemistry. Hua, Q. X., and Weiss, M. A.
Mechanism of insulin fibrillation: the structure of insulin under amyloidogenic conditions resembles a protein-folding intermediate. J. Biol. Chem. 2004;
279:21449–21460. © the American Society for Biochemistry and Molecular Biology. C, schematic nucleation pathway of insulin fibrillation is mediated by
aggregation of a distorted monomeric conformation (black trapezoid at center; adapted with permission from Yang et al. (30) (This research was originally
published in the Journal of Biological Chemistry. Yang, Y., Petkova, A., Huang, K., Xu, B., Hua, Q. X., Ye, I. J., Chu, Y. C., Hu, S. Q., Phillips, N. B., Whittaker, J.,
Ismail-Beigi, F., Mackin, R. B., Katsoyannis, P. G., Tycko, R., and Weiss, M. A. An Achilles’ Heel in an amyloidogenic protein and its repair: insulin dynamics,
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naling among insulin analogs (other families of growth factors).
In the future, this approachmay be extended from two genes to
gene-regulatory networks.
SCI-a demonstrated no increased activation of mitogenic
pathways relative to WT insulin and lispro. Notably, SCI-b
showed a similarly low level of cyclin D1 accumulation (Fig. 6B)
in both cell lines. Although not originally intended as a candi-
date therapeutic, these data suggest that SCI-b may also be safe
for clinical use10 despite demonstrating delayed blood-glucose
recovery (through unknownmechanisms) on i.v. injection (Fig.
2). These results correlate with (but aremore informative than)
in vitro receptor-binding affinities of SCIs for IR-A, IR-B, and
IGF-1R ( Table S2). This study has thus demonstrated novel
ultra-stable insulin analogs that appear not to be mitogenic,
raising confidence in their safety for potential human use.
Although biased agonists of G-protein–coupled receptors
have been identified (76), such syntheticmolecules have not yet
been discovered in the context of receptor tyrosine-kinase net-
works, including the IR. Naturally-occurring biased agonists of
IR include insulin, which favors Akt-mediated metabolic path-
ways, and IGF-II, which preferentially activates mitogen-acti-
vated protein kinase (MAPK)-mediated mitogenic pathways
(51). An example of biasedmetabolic stimulation has been pro-
vided by a recent study of an insulin-mimetic peptide that
favored activation of hepatic lipid metabolism in an obese
rodent model of type 2 diabetes mellitus (77). As the search for
metabolic-biased and/or non-mitogenic insulin therapeutics
expands (2), this study has described a straightforward rt-qPCR
method for screening themitogenic signaling activities of novel
analogs with minimal sample consumption. Furthermore, our
results obtained from two cell lines (L6-IRA and MCF-7) sug-
gest that the rt-qPCRmethod can be extended to other cellular
models pertinent to insulin action, such as primary hepatocytes
in culture. Future development of this technique may enable
identification of analogs that preferentially stimulate Akt-me-
diated pathways relative to MAPK-mediated pathways.
Enhanced solubility and decreased aggregationmay offer
clinical advantages
The net negative charge of SCI-a at neutral pHwas enhanced
by substitutions LysB293 Glu and TyrA14 3 Glu (offset to a
limited extent byHisA8). Its IEF-defined isoelectric point (Table
5) was reduced by0.6 units relative to WT insulin. This shift
was associated with enhanced solubility (7 mM by turbidime-
try (78) and rp-HPLC (79)) in a buffer compatible with pharma-
ceutical formulation. Concentration-dependent precipitation
of SCI-a or SCI-b was not observed, in striking contrast to WT
insulin (60% soluble at 7 mM; Fig. 4B). SEC studies suggested
that, under conditions similar to those in an SQ depot (Fig. 4C),
WT insulin in the concentration range of 5–7 mM forms a het-
erogeneous mixture of aggregates, whereas at these concentra-
tions SCIs were predominantly dimeric (SCI-a) or monomeric
(SCI-b). DLS likewise indicated that the SCIs are less prone
than WT insulin to form large protein aggregates.
Aggregation and precipitation are significant general barri-
ers to development of high-concentration solutions of thera-
peutic proteins. In the case of insulin there is a growing clinical
need due to increasing prevalence of marked insulin resistance
(defined as200 units of insulin per day) (80). Such high insu-
lin requirements are primarily encountered in obese patients
but may also be associated with lipodystrophy and in preg-
nancy. Use of standard insulin formulations (0.6 mM) in such
patients requires large injection volumes, which can be painful
and inconsistently absorbed (80). Interest in ultra-concentrated
insulin formulations has been further generated by innovative
engineering efforts to miniaturize insulin pumps, including
implantable devices for intraperitoneal delivery (80).
Unfortunately, aggregation ofWT insulin at high concentra-
tions markedly delays its SQ absorption (38). Thus, rather than
being rapid-acting as a regular U-100 insulin formulation,
Humulin R U-500 (3 mM; Lilly) exhibits the prolonged PD
properties of a twice-a-day microcrystalline insulin suspension
(Neutral Protamine Hagedorn) due to delayed subcutaneous
absorption (80). In small clinical trials, U-500 treatment of
patients with marked insulin resistance was nonetheless asso-
ciated with better glycemic control than was achieved in the
same patients treated with U-100 formulations (81). Off-label
use of U-500 in insulin pumps has also been described despite
safety concerns regarding prolonged hypoglycemia following
overdelivery (80). These observations have led to the recent
reformulation of insulins lispro and aspart (AspB28-insulin) at
double the standard strength (U-200 or 1.2 mM (82)), near the
limit of concentration as rapid-acting products.
Our results hold promise to the development of ultra-
concentrated and yet rapid-acting insulin formulations. The
remarkable solubility of SCI-a (7 mM) and its limited aggre-
gation under these conditions in principle makes possible rap-
id-acting U-500 formulations and even strengths U-1000.
Such applications might enhance the efficacy and safety of
multi-injection regimens in patients with marked insulin resis-
tance and enable next-generation external and implanted insu-
lin pumps (80).
Concluding remarks
The coming years will soonmark the 50th anniversary of the
crystal structure of insulin (1969) and centennial of its discov-
ery (1921). The intervening decades have been remarkable for
the interplay between basic science and its translation. Pharma-
ceutical manufacture of recombinant human insulin, for exam-
ple, has long exploited proinsulin or “mini-proinsulin” analogs
as production intermediates (16, 25, 26). The latter exhibit
more efficient folding and secretion in yeasts Saccharomyces
cerevisiae and Pichia pastoris than does proinsulin, enhancing
10 Our accompanying article (8) discusses the possible utility of SCI-b as a
biphasic agonist with PD properties analogous to current premixed
formulations.
Table 5
Isoelectric points of WT insulin and SCI analogs
Analog
Isoelectric point (pI)
Predicteda IEFb
WT insulin 5.4 5.8
SCI-a 4.9 5.2
SCI-b 4.8 5.1
a Data were calculated using protein sequence and ProtParam.
b Data were as measured by IEF electrophoresis.
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fermentation yields (25, 27). Increased in vitro folding efficiency
has likewise been described in a synthetic 49-residue “des-Di”
polypeptide containing a peptide bond between residues B28
and A1 (63).
In this and our accompanying article (8), we have sought to
extend the role of an SCI from manufacturing intermediate to
therapeutic protein. This extensionmay provide an ultra-stable
template by which to prolong shelf life and circumvent the
global cold chain of insulin distribution, with particular utility
in developing regions experiencing high year-round tempera-
tures and sparse access to refrigeration (32). Furthermore, the
resistance of SCI-a to higher-order self-assembly at high pro-
tein concentrations may enable, for the first time, development
of ultra-high-strength rapid-acting insulin formulations. Such
applications motivated foundational studies of structure and
function with a focus on the identification of Achilles’ heels in
the protein fold that, when exploited through conformational
fluctuations, results in the formation of amyloid nuclei and
fibrils that underlie physical degradation (30). Suchweakness in
native two-chain insulins is avoided with the foreshortened C
domain of SCIs, which provides a topological barrier to amyloid
fibril formation (29, 30), enhancing physical stability and
thereby extending projected pharmaceutical shelf life.
The present findings have uncovered salient questions for
further investigation. How flexible are connecting domains,
and to what extentmight the dynamics of the tether be coupled
to conformational fluctuations in the globular portion of the
structure? How do the structural and dynamic properties of an
SCI enable its engagement by the insulin receptor? Finally, what
controls the duration of signaling at the cellular level, and in
particular why are some ultra-stable analogs associated with
aberrant prolongation of signaling in vivo? This and our accom-
panying article (8) promise to provide a foundation for address-
ing these questions.
Experimental procedures
Construction of SCI expression vectors
Aset of plasmids (pPICZ) was constructed for expression in
yeast P. pastoris directing secretion of SCI precursors into
media (21, 83). A template plasmid for SCI precursors, desig-
nated pPICZTKSCI-c, was first constructed from a synthetic
gene purchased from Genscript (Piscataway, NJ) encoding
(from 5
 to 3
) the following: (i) an -factor pre-pro-leader and
Kex2-cleavage site (EKR) connected to (ii) spacer sequence
(EEAEAEAEPK); both are N-terminal to (iii) the coding
sequence of SCI-c. An XbaI site was included at the 3
-end to
facilitate cloning; codon usage was optimized for expression in
P. pastoris. The synthetic gene was cloned into the XhoI and
XbaI sites (respective nucleotides 1185 and 1272) (84). Follow-
ing sequence verification (Molecular Cloning Laboratories, San
Francisco), this construct provided a template for synthesis (via
the QuikChange site-directed mutagenesis kit from Agilent,
Santa Clara, CA) of pPICZA plasmids encoding precursors
of SCI-a, SCI-b, or variant “mini-proinsulins” (MPI); the lat-
ter encodes single-chain precursors of two-chain analogs
[AspB10]insulin, 4SS-DKP, and DKP insulins (respectively des-
ignated DB10-MPI, 4SS-DKP-MPI, and DKP-MPI), where
“DKP” denotes substitutions AspB10, LysB28, and ProB29. For
construction of MPI derivatives from pPICZTKSCI-c, a long
single-stranded DNA primer (Ultamer from Integrated DNA
Technologies, Coralville, IA) was amplified by PCR, and the
purified product was used as a primer in the QuikChange reac-
tion according to the manufacturer’s instructions. DKP-MPI
differs from insulin lispro in three respects: (a) addition of
HisB103Asp; (b) deletion of B30; and (c) incorporation of short
tripeptide sequence EWK connecting B29 to A1. 4SS-DKP-
MPI has the same sequence asDKP-MPI, but with IleA103Cys
andGlnB43Cys, enabling formation of fourth disulfide linkage
(cystine A10–B4 (33)). DB10-MPI possesses the WT insulin
sequence except for AspB10 and EWK linker. Final PCR prod-
ucts were amplified and isolated from Escherichia coli DH5
cells as described by the vendor (EasySelect Pichia Expression
kit; Invitrogen), followed by sequence verification (Molecular
Cloning Laboratories).
Biosynthesis of SCI precursor
Biosynthesis of SCI precursors followed an established pro-
tocol (85). First, electroporation of competent P. pastoris strain
X33with isolated SCI-precursor pPICZ plasmid (correspond-
ing to either SCI-a, SCI-b, SCI-c, DKP-MPI, or 4SS-DKP-MPI)
was performed with Gene Pulser II (Bio-Rad) as described in
the EasySelect Pichia Expression kit (Invitrogen) followed by
selection on sterile YPDA Z plates (1% yeast extract, 2% pep-
tone, 2% dextrose, 2% agar, 100 g/ml Zeocin). After 3 days of
incubation at 30 °C, protein expression by transformant colo-
nies was assessed via small-scale culture in 50-ml Falcon tubes.
Colonies were inoculated into 10-ml autoclave-sterilized
YPS  Z media (1% yeast extract, 2% peptone, 0.1 M sorbitol,
100 g/ml Zeocin) and grown for 24 h at 30 °C with stirring
speed 225 rpm (C25KC Incubator/Shaker; New Brunswick Sci-
entific, Edison, NJ). Cells were then diluted into new 10-ml
volumes of YPS  Z to an A600 nm of 0.33 and incubated for 3
days at 30 °C with 225 rpm stirring; methanol was added to 1%
after the first 24 h and to 0.5% at 48 and 72 h. After pelleting
(1500  g for 5 min), 19 l of each culture’s supernatant was
analyzed by SDS-PAGE (NuPAGE 12% BisTris; Life Technolo-
gies, Inc.) to assess relative SCI-precursor expression levels.
After verifying the presence of the SCI precursor (7601, 7587,
and 7455 Da for SCI-a, SCI-b, and SCI-c precursors, respec-
tively) in the supernatant by matrix-assisted laser-desorption
ionization/time-of-flight mass spectrometry (MALDI-TOF
MS; 4700 Proteomics Analyzer; Applied Biosystems, Foster
City, CA), the colony presenting the most intense SCI-precur-
sor band (at 6–8 kDa) by SDS-PAGE was selected for post-
transformational vector amplification (86). Iterative amplifica-
tion, adapted for the SCI system, increased pPICZ plasmid
copy number (and thereby SCI-precursor expression (87)) by (i)
growing colonies overnight in 10 ml of YPS  Z media (30 °C
with 225 rpm stirring); (ii) streaking cells on YPDA selection
plates containing increasing Zeocin concentration (200, 400,
1000, and finally 2000 g/ml); (iii) expression screening (as
above) of amplified colonies; and (iv) regrowth of the highest-
expressing strain followed by selection on YPDA plates con-
taining the next Zeocin concentration step. Iterative amplifica-
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tion (i.e. repeating steps i–iv above) was stopped once a strain
resistant to 2000 g/ml Zeocin was obtained.
For scaled SCI-precursor production, cells were inoculated
in a flask containing 100 ml of YPG  Z (1% yeast extract, 2%
peptone, 2% glycerol, 100 g/ml Zeocin) and grown to 20
A600 nm at 30 °C with stirring. Cells were then added to fermen-
tation medium (5% glycerol, 2% (NH4)2SO4, 1.2% KH2PO4,
0.47%MgSO47H2O, 0.036% CaCl22H2O, 1% yeast extract, 1%
peptone, and 0.5% fermentation Pichia trace metal 1 (PTM1;
Bioworld, Dublin, OH)) in a fermentation vessel (BioFlo310,
New Brunswick Scientific, Edison, NJ) to a final 0.25 A600 nm.
Expression of an SCI precursor was induced by adding metha-
nol to 1%. After fermentation, supernatant containing SCI pre-
cursors was collected by centrifugation and purified (see
below).
Purification of recombinant yeast product
Hydrophobic-interaction chromatography (butyl-Sepharose
4 Fast Flow resin; GE Healthcare) was used to capture the SCI
precursors. Purifications by rp-HPLC were performed using
0.1% trifluoroacetic acid (TFA) in water as aqueous mobile
phase (buffer A) and 0.1% TFA in acetonitrile as the organic
modifier (buffer B). Preparative purifications utilized a Waters
2545 quaternary pumping systemwith FlexInject (Waters). The
SCI precursors were isolated by preparative C4 rp-HPLC (C4
Proto 300 Å, 10-m, 20  250 mm; Higgins Analytical Inc.,
Mountain View, CA). Eluted SCI precursors were collected and
lyophilized.
Preparation of ACP-1 protease
A gene encodingAchromobacter protease I (ACP-1), derived
from Achromobacter lyticus (88), was cloned into a pET15b
plasmid; its sequence contained substitution Lys30 3 Arg (to
enhance stability) and a C-terminal His tag (GSGSHHHHHH;
to enable affinity purification). The plasmid was transformed
into competent E. coli cells (strain BL21(DE3) pLysS as
described by the vendor; Promega,Madison,WI)with selection
on lysogeny broth (LB) plates containing 100 g/ml ampicillin
and 34 g/ml chloramphenicol. ACP-1-expressing cells were
grown at 37 °C in LB media (with antibiotics) to 1.0 A600 nm
followed by induction with 0.8 mM isopropyl -D-1-thiogalac-
topyranoside for 20 h at 25 °C. Cells were collected by centrif-
ugation, washed in 100mMTris-HCl (pH 8.0), and resuspended
in buffer containing 100 mM Tris-HCl (pH 8.0), 1 mM EDTA,
and 20% sucrose. Cells were lysed via 10 min of gentle agitation
in the presence of lysozyme (0.2 mg/ml) at 25 °C followed by
addition of ice-cold water to lysate for 10 min. Lysates were
centrifuged at 2500  g (Centrifuge 5810R; Eppendorf, Haup-
pauge, NY) for 15 min. To immobilize His-tagged ACP-1,
supernatants were incubated with Ni-Sepharose Fast Flow
resin (GE Healthcare) at 25 °C for 1 h, rinsed with wash buffer
(50 mM sodium phosphate (pH 6.5), 300 mM NaCl, 2 mM imid-
azole), and resuspended in digestion buffer (25 mM Tris-HCl
(pH 8.5), 1 mM EDTA, 0.1 M urea).
Enzymatic cleavage of SCI precursor
Enzymatic conversion of the SCI precursors to SCI (effected
via cleavage of the EEAEAEAEPK decapeptide at the C termi-
nus of lysine) was achieved by gently rocking (at 25 °C) a 2
mg/ml solution of SCI precursor in digestion buffer containing
ACP-bound resin (see above). Preparative C8 rp-HPLC (C8
Kromasil 100 Å, 10-m, 20  250 mm; Akzo Nobel, Amster-
dam, Netherlands) isolated the target SCI. Final purification
utilized a C18 column (C18 Proto 300 Å, 10-m, 200  250
mm; Higgins Analytical Inc.); the mass of the eluted SCI was
verified by MALDI-TOF MS (6517, 6503, and 6371 Da for
SCI-a, SCI-b, and SCI-c, respectively). Purities were assessed
using analytical C18 rp-HPLC (C18 Discovery BIOwide 300 Å,
5-m, 4.6  250 mm; Supelco, Bellefonte, PA). Purities 98%
were achieved.
Enzymatic semi-synthesis of insulin analogs
Two-chain insulin analogs were prepared by trypsin-cat-
alyzed semi-synthesis (89) using variant des-octapep-
tide(B23–B30)-insulin (DOI) fragments containing AspB10
(with or without cystine A10–B4) as described (46). These
fragments were generated by tryptic digestion of AspB10-
MPI, DKP-MPI, or 4SS-DKP-MPI isolated from P. pastoris
cultures followed by preparative C8 rp-HPLC purification as
above. Final and in-process purities were assessed using C18
analytical rp-HPLC as above. Eluates were lyophilized. Fol-
lowing semi-synthetic linkage of variant DOI and octapep-
tide, the analogs were purified by C4 preparative rp-HPLC as
above. The analog was lyophilized, and its mass was verified
by MALDI-TOF MS.
Purification of control insulin analogs
WT insulin, insulin lispro, and insulin glargine were purified
from respective products Humulin, Humalog (both from
Lilly), and Lantus (Sanofi-Aventis, Paris, France) by prepara-
tive C4 rp-HPLC as above. Eluted proteinswere lyophilized and
stored at20 °C until use.
Formulation-compatible buffers
SCIs and control insulin analogs were dissolved at stated
concentrations in either Lilly Diluent (a product containing
3.8 mg/ml sodium phosphate (pH 7.4), 16 mg/ml glycerin,
1.6 mg/mlmeta-cresol, 0.65 mg/ml phenol) or, in the case of
insulin glargine, a solution similar to that in Lantus as pre-
pared in accordance with the product insert (2.7 mg/ml
meta-cresol, 16 mg/ml glycerin, with pH adjusted to 4.0 with
NaOH and HCl, but without inclusion of polysorbate 20).
ZnCl2 was then added to a ratio of 3 Zn2:1 insulin hexamer.
Isoelectric focusing
Isoelectric points (pI) of SCIs andWT insulinweremeasured
by IEF gel electrophoresis using a 5–10-g protein samples
(79). Experimental pI values were calculated via a linear plot of
migration distance versus pHgradient of the IEF standards (79).
Estimates of pI predicted on the basis of protein sequence were
generally lower than gel-derived values.
Studies of protein solubility and aggregation
Lyophilized proteins (3–5 mg) were dissolved in 1 ml of
deionized water with pH adjustment to 7.4 with dilute NaOH.
Protein content was measured by UV absorbance (Nanodrop
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2000C spectrophotometer; Thermo Fisher Scientific, Wal-
tham, MA). DLS samples were degassed and syringe-filtered
(0.02-mWhatmanAnotop 10 filters; Sigma). Aliquots nec-
essary to obtain respective 7, 5, 2, and 1mM protein solutions in
30-l final volumes were pipetted into separate Eppendorf
tubes and lyophilized. The powder was then dissolved in “Tris
diluent” (25 mM Tris-HCl (pH 7.4) containing 16 mg/ml glyc-
erin, 1.6mg/mlmeta-cresol, 0.65mg/ml phenol, and ZnCl2 at a
ratio of 3 Zn2 ions per insulin hexamer; Tris-HCl was substi-
tuted for sodium phosphate (as in Lilly Diluent; see above) to
avoid interaction between phosphate anions and zinc cations to
formaprecipitate). ForDLS samples, all buffer components (i.e.
deionized water, 4 Tris-HCl diluent (pH 7.4), and 10 mM
ZnCl2)were degassed via nitrogenbubbling for 15min and then
syringe-filtered as above, followed by centrifugation (5 min at
16,100  g). Gentle mixing of the filtered components with
lyophilized protein was performed by repeated pipetting. Once
mixed, sampleswere incubated at room temperature for 30min
before use.
Turbidimetry
Possible precipitation of insulin in the protein concentra-
tion range 1–7 mM in Tris Diluent (above) was assessed by
500 nm absorbance as described (78) using a Nanodrop
2000C (Thermo Fisher Scientific) with 2-l samples per
measurement.
HPLC-based assessment of solubility
Solubility was assessed by rp-HPLC as described (79). In
brief, insulin analogs were made 1–7 mM in Tris Diluent
(above). 2-l aliquots weremixed with 98l of deionized water
and analyzed by C4 analytical rp-HPLC (C4 Proto 300Å, 5-m,
250 4.6 mm; Higgins Analytical Inc.). The stock insulin solu-
tion was then centrifuged for 5 min at 16,100  g (Centrifuge
5415D; Eppendorf) to remove any precipitates and another 2l
was analyzed by C4 analytical rp-HPLC as above. The insulin
peak in each chromatogram was integrated in the Empower
HPLC software (Waters), and data were presented as the ratio
of peak area of the non-centrifuged sample to that of the cen-
trifuged sample, yielding percent recovery, which reflects the
fraction of protein that is fully dissolved at stated concentra-
tions (1–7 mM). Error presented in these measurements was
obtained by replicate injection of 10 g of Humalog (0.6 mM
insulin lispro at pH 7.4), which revealed6–10% random error
between injections. Injection of known quantities of insulin lis-
pro in water (quantitated byUV absorbance) provided a control
for losses unrelated to solubility; percent recoveries of insulin
lispro were typically between 85 and 90%.
Size-exclusion chromatography
Self-assembly ofWT insulin and SCIs (1–7mM)was analyzed
by SEC as described previously (90). Insulins in Tris-HCl dilu-
ent (10 l injection) at stated concentrations were analyzed by
SEC (Enrich SEC-70 10  300-mm column; fractionation
range 0.5–70 kDa; Bio-Rad) using a 1 ml/min isocratic flow
of mobile phase (10 mM Tris-HCl (pH 7.4), 145 mM NaCl,
and 0.01% sodium azide). Molecular weights of eluted peaks
were interpolated as described (90) from a linear regression
analysis of the elution volumes, Ve, of known molecular
weight standards. Briefly, thyroglobulin (669 kDa) was used
to determine void volume, V0. The calibration curve (Fig. S5)
used to determine the molecular mass of insulin samples was
then obtained from a semi-log plot of the Ve/V0 versus the
known molecular mass of the following gel filtration stan-
dards (Sigma): ovalbumin (45 kDa), carbonic anhydrase (29
kDa), myoglobin (17 kDa), cytochrome c (12.4 kDa), and
aprotinin (6.5 kDa).
Dynamic light scattering
Protein-free Tris-HCl diluent or Tris-buffered insulin solu-
tion (pH 7.4) was placed in a low-volume Wyatt microcuvette
(25-l sample volume) and 90° scattering data collected for 30
min (10-s correlation averaging time) using aWyatt miniDawn
TREOs instrument equipped with a quasi-elastic light-scatter-
ing autocorrelator module with subsequent data analysis
performed in ASTRA 6 (all from Wyatt Technology Corp.,
Santa Barbara, CA). Protein-free samples gave only shot
noise, indicating that themixing protocol does not introduce
bubbles. Size distributions of insulin samples were obtained
using the regularization (91) processing protocol in ASTRA
6. As more concentrated protein samples (e.g.WT insulin at
7 mM) had a high incidence of large aggregates resulting in
spurious bursts in count rate that confound analysis, regu-
larization analysis was applied only to regions of stable count
rate; 5–10 correlation functions were averaged to obtain
each distribution.
Receptor-binding assays
Affinities of insulin or insulin analogs to the A and B isoform
of the insulin receptor and to the insulin-like growth factor 1
receptor (IGF-1R) were measured in a competitive-displace-
ment assay as described (46). Data for homologous and heter-
ologous receptor bindingwere analyzed as described previously
(92).
Guanidine denaturation studies
Thermodynamic stabilities of all insulin peptides in KPi
buffer (10 mM K2HPO4/KH2PO4 (pH 7.4) with 50 mM KCl) at
25 °C were determined by monitoring guanidine-induced
unfolding at the helix-sensitivewavelength of 222nmwith aCD
spectropolarimeter (Aviv Biomedical Inc., Lakewood, NJ)
equipped with temperature control and an automated titration
unit, as described previously (46). Using non-linear least-
squares regression, plots of ellipticity versus guanidine concen-
tration were fit to a two-state unfolding model (93) as shown in
Equation 1,
c 
AB e
Gmc/RT
1 eGmc/RT
(Eq. 1)
where G is the Gibbs free energy of unfolding; c is guanidine
concentration; R is the ideal gas law constant; T is absolute
temperature, andA andB are baseline ellipticity values rep-
resenting the folded and unfolded state. Baseline ellipticities
were calculated via simultaneous fitting of linear equations
A(c)AmAc andB(c)BmBc, as described previ-
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ously (94).
Fibrillation assays
Insulin fibrillation wasmonitored in solutions containing 0.6
mMprotein dissolved in LillyDiluent (pH 7.4) or, in the case of
insulin glargine, a Lantus-like solution (see above), in each
case with gentle rocking at 45 °C in the presence of an air–
liquid interface. The solutions were incubated in sealed glass
vials. Aliquots were taken at regular intervals and frozen to
enable analysis of thioflavin T fluorescence at assay termina-
tion, which occurred on visual appearance of cloudiness
(46).
NMR spectroscopy
Spectra were acquired at pH 7.4 in 10%D2O, 90%H2Owith a
Bruker AVANCE 700 MHz spectrometer equipped with a tri-
ple-resonance cryoprobe (Bruker Biospin Corp, Billerica, MA),
as described (46). Data were processed using Bruker’s TopSpin
software.
X-ray crystallography
Lyophilized SCI-a was dissolved in 0.02 N HCl to a concen-
tration of 10mg/ml; crystallization trials employed sitting-drop
vapor diffusion. The best diffracting crystals were obtained at
20 °C with a 1:1 volume ratio of SCI-a mixed with well solution
containing 0.2 M MgCl2, 15% w/v polyethylene glycol (PEG)
8000, and 0.1 M Tris-HCl (pH 8.5). Single crystals were har-
vested with a nylon cryoloop and immersed in perfluoropoly-
ether cryoprotectant oil (Hampton Research, Aliso Viejo, CA)
to remove mother liquor before submerging in liquid nitrogen
for storage.
Diffraction data were collected at SSRL BL7-1 from a single
cryo-cooled crystal using a Quantum 315r CCD detector (Area
Detector SystemsCorp., Poway, CA). Data were processedwith
XDS (95), and the structure was solved by molecular replace-
ment using PHASER (Table 2) (96). A search model was con-
structed using amonomer from a high-resolution crystal struc-
ture of WT insulin (PDB code 1GUJ (44)) with residues
renumbered 1–57 in accordance with the nomenclature of
SCI-c as studied previously byNMR (PDB code 2JZQ (29)). The
57 residues thus consist of a B domain (residues 1–30), C seg-
ment (residues 31–36), and A domain (residues 38–57). Side
chains of non-conserved residues in the search model were
computationally truncated to Ala. Molecular replacement cal-
culations with this monomer (residues Gln4–Tyr26 and Gly37–
Asn57) located six copies that form a hexamer in the asymmet-
ric unit of the P21 unit cell to give a calculatedVm of 2.03 Å3/Da
and solvent content of 39%. After rigid body and restrained
refinement in Refmac (97), side chains of non-conserved resi-
dues as well as additional residues not present in the original
search model were built into electron-density maps using Coot
(98). Iterative cycles of model building were alternated with
refinement calculations using Phenix (Table 2) (99). Composite
refined omit maps were calculated to generate density with
minimal search model bias. Refinement calculations were car-
ried out with and without non-crystallographic symmetry
restraints; release of the restraints resulted in amodest decrease
of the refined R-factor (25.1 to 24.7%) but a significant increase
in RFree (31.4–33.1%). The final model was refined with non-
crystallographic symmetry restraints and against F  0F. In
each monomer, between 7 and 9 residues in the linker (and
adjoining BC and CA junctions) could not be located in density
and were presumed to be flexible or disordered. The six mono-
mers were labeled as chains A–F. Using this convention, the
final model consisted of residues GlnA4–ThrA27 and GlyA37–
AsnA57; GlnB4–ProB28 and GlyB37–AsnB57; HisC5–ThrC27 and
GlyC37–AsnC57; GlnD4–ProD28 and ArgD36–AsnD57; GlnE4–
ProE28 and ArgE36–AsnE57; HisF5–ThrF27 and GlyF37–AsnF57.
In total, therewas a lack of continuous, interpretable density for
20% of the expected amino acids, which were not built into
the final model. These are located at the N termini (residues
1–4) and in the B and C domain segments B27–B30 and C1-C6
(together comprising residues 27–36) of eachmonomer and are
presumed to be flexible or disordered. As these disordered res-
idues represent a significant fraction of the total molecule that
yields non-continuous electron density not accounted for in
either the refinement model or the uniform density bulk sol-
vent model, they may contribute to the slightly high RFree
(31.4%) which nonetheless gives a reasonable RFree–R-factor
difference of7%.
Biological testing in diabetic rats
The insulin analogs were dissolved at concentrations speci-
fied in the legends to Figs. S1, S2, and S5 in either LillyDiluent
or, in the case of insulin glargine, a Lantus-like acidic solution.
The formulations each contained ZnCl2 at a ratio of 3 Zn2:1
insulin hexamer. Insulin purity was verified by C4 analytical
rp-HPLC as above. Protein-free Lilly Diluent was used as a
negative control (buffer only).
Groups of male Lewis rats (mean body mass 300 g) ren-
dered diabetic by streptozotocin (100) were utilized. Rats were
injected either SQ or i.v. at time t 0 with the specified dose of
insulin (100 l/300 g of body mass). For i.v. injection, animals
were placed in an induction chamber and anesthetized using 5%
isoflurane in 100% oxygen. While under anesthesia, the tail of
the rat was washed with lukewarm water and further cleaned
with gauze containing alcohol and/or xylene. WT insulin or
insulin analogs were injected at specified doses into the lateral
tail vein.
Following SQ or i.v. injection, a small drop of blood was
obtained from the clipped tip of the rats’ tails at t 0 and then
every 10 min for the 1st h, every 20 min for the 2nd h, every 30
min during the 3rd h and then once per h for the remainder of
the experiment. Measurements of [glucose] were made using a
clinical glucometer (EasyMax V Glucose Meter; Oak Tree
Health, Las Vegas, NV). Because of day-to-day variation (even
in the same rat on different days), 4–8 rats were injected per
analog formulation on each test day, and the experiments were
repeated on one or more non-consecutive days to obtain a
larger sample size.
Thermal inactivation assays
Heating of SCIs and control analogs was performed in an
oven at either 45 or 75 °C with gentle rocking. Protein solu-
tions were incubated in sealed glass vials at a concentration
of 0.6 mM (nominal U-100 strength in the case ofWT insulin,
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insulin lispro, or insulin glargine) in either Lilly Diluent or,
in the case of insulin glargine, in an acidic solution similar to
that in Lantus (above). At stated time points in Fig. 5, sam-
ples were assessed for residual potency by diluting 10-fold
(to a nominal strength of U-10; 0.06 mM) in their appropriate
buffer (Lilly Diluent (pH 7.4) or Lantus-like solution (pH
4.0)) before SQ injection at stated doses into diabetic rats
(see above).
To obtain a quantitative assessment of residual insulin
action, a customMATLAB (MathWorks, Natick, MA) script
was written to process rat glucose measurements in batch.
AUCs were calculated for each individual data set using trap-
ezoidal numerical integration. Two reporters of functional
degradation were then determined: fractional AUC and per-
cent activity. Fractional AUC was defined as the ratio of
average AUC for a heat-stressed analog’s dataset to the aver-
age AUC of the fresh (unstressed) analog. This value defined
as fully active the fresh analogs, corresponding to a fractional
AUC of 1.0, whereas partially or fully inactivated samples
exhibited fractional AUCs 1.0. To further quantify the
degree of thermal inactivation, percent activity was calcu-
lated: the average AUC of fresh or heated datasets was sub-
tracted from the average AUC of diluent-only control injec-
tions to yield area over the curve (AOC). AOC for the heated
dataset was divided by the AOC of the unheated sample,
yielding a percentage. Fully active samples thus had the same
AOC as the fresh sample (i.e. 100% active), whereas com-
pletely inactivated analogs had the same glucose-response
curve as diluent-only (i.e. AOC  0). Because of biological
variability among rat responses, the heated insulin curves
can have a lower AUC than that of the diluent-only curve,
resulting in apparent negative values for percent activity;
this corresponded to complete inactivation.
Signaling assays inmammalian cell culture
Signaling activities of the insulin analogswere tested in (a) L6
cells (rat myoblasts) engineered to overexpress human IR-A
(49) and (b)MCF-7 human breast adenocarcinoma cells (which
express IR-A, IR-B and high levels of IGF-1R (50)). L6-IRA cells
were cultured in DMEM supplemented with 10% fetal bovine
serum (FBS) and G418 antibiotic for selection. MCF-7 cells
(American Type Culture Collection, Manassas, VA) were cul-
tured in Eagle’s minimum essential medium supplemented
with 10% FBS, 1% penicillin/streptomycin, and sodium pyru-
vate (1 mM). 24-h serum-starving protocol using appropriate
culture medium except FBS was applied at 70–75% cell conflu-
ence (0.8 106 cells per well (L6-IRA) and 6 106 per 10-cm
dish (MCF-7)). After serum-starving, serum-free medium con-
taining 100 nM insulin analogs was added to each well (control
wells received medium with no added insulin). Media were
removed after 15 min, followed by cell lysis using RIPA buffer
with protease and phosphatase inhibitors (Cell Signaling Tech-
nology, Danvers, MA). Protein concentrations in cell lysates
were determined with a Pierce BCA assay kit (Thermo Fisher
Scientific) for use in immunoblotting. Cells cultured for
rt-qPCR assays (see below) were, after 24 h of serum starvation,
treated with either a protein-free medium or medium supple-
mented with an insulin analog (to a hormone concentration of
100 nM) medium for 8 h.
Real-time qPCR transcriptional assay
Mitogenic gene transcription was measured in triplicate by
rt-qPCR with samples prepared according to the One-step rt-
qPCR kit (Bio-Rad).
The following sets of primers (5
–3
) were used for L6-IRA
cells: cyclin D1, GCCGAGTGGAAACTTTTGTCG and CGG-
GAAGCGTGTACTTATCCT; cyclin G2, GCAAGAAAAGA-
AGCCAAGCT and TGACCAAGAGGCAAAATAAAAT-
CAA; glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
GACATGCCGCCTGGAGAA and GCCCAGGATGCCCTT-
TAGT; and TFIID, CTGAGGGGGCAATGTCTAAC and
GGGCAGCTAGTGAGATGAGC.
For MCF-7 cell-based assays, the following primers (5
–3
)
were used: cyclin D1, AATGACCCCGCACGATTTC and TCA-
GGTTCAGGCCTTGCAC; cyclin G2, ATCGTTTCAAGGC-
GCACAG and CAACCCCCCTCAGGTATCG; GAPDH, AG-
CCGAGCCACATCGCT and TGGCAACAATATCCACTT-
TACCAGAGT; and TFIID, GCACAGGAGCCAAGAGTGAA
and TCACAGCTCCCCACCATGTT.
Insulin-stimulated protein phosphorylation
Samples contained 2–5g (for L6-IRA) or 25g (forMCF-7)
of protein from cell lysate in each loading well (as quantitated
by BCA assay). Cell lysates were dissolved in Laemmli buffer
(Bio-Rad) with 10% -mercaptoethanol, heated at 100 °C for 5
min (for all Akt/p-Akt blotting), 50 °C for 10 min (for L6-IRA
IR/p-IR), or 100 °C for 8 min (for MCF-7 IR/p-IR) and then
centrifuged at 9300 g for 1 min (Biofuge A; Baxter Scientific,
Soddy Daisy, TN). Samples were loaded into 10% Mini-
PROTEAN TGX gels (Bio-Rad). Proteins were transferred to
0.2-mPVDFmembrane and then blocked in 5% bovine serum
albumin (or 10% milk for p-Akt data) for 1 h. All antibodies
were purchased from Cell Signaling Technology unless other-
wise stated. Membranes were incubated overnight at 4 °C with
insulin receptor  (4B8) rabbit monoclonal antibody (mAb) or
an equal mixture of phospho-insulin receptor  (Tyr1150/1151)
rabbit mAb; phospho-insulin receptor (Tyr1158) polyclonal
antibody (Thermo Fisher Scientific); phospho-insulin receptor
(Tyr1334) polyclonal antibody (Thermo Fisher Scientific);
phospho-insulin receptor  (Tyr1345) rabbit mAb; and anti-
insulin receptor (phospho-Tyr972) antibody (Abcam, Cam-
bridge, UK). Dilutions for these antibodies were 1:5000 in 5%
bovine serum albumin. Antibodies for Akt blotting were
p-Akt1/2/3 antibody (Ser473) (1:1000) and Akt1/2/3 anti-
body (H-136) (1:2000). For MCF-7 samples, the following
anti-Akt antibody dilutions in 10% milk were used: p-Akt1/
2/3 antibody (Ser473) (1:1000) and Akt1/2/3 antibody
(H-136) (1:2000). After the primary antibody incubation,
membranes were washed with Tris-buffered saline with 0.1%
Tween 20 and incubated in goat anti-rabbit HRP-conjugated
secondary antibody diluted 1:10,000 in 5% bovine serum
albumin (or 10% milk for p-Akt data) for 1–2 h at room
temperature. All membranes were washed three times with
1 Tris-buffered saline, 0.1% Tween 20 and incubated in
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Luminata Crescendo Western HRP Substrate (Merck Milli-
pore, Billerica, MA) for 45 s and developed.
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